PL3244912T3 - Leczenie liksysenatydem pacjentów pediatrycznych z cukrzycą typu 2 - Google Patents
Leczenie liksysenatydem pacjentów pediatrycznych z cukrzycą typu 2Info
- Publication number
- PL3244912T3 PL3244912T3 PL16700758T PL16700758T PL3244912T3 PL 3244912 T3 PL3244912 T3 PL 3244912T3 PL 16700758 T PL16700758 T PL 16700758T PL 16700758 T PL16700758 T PL 16700758T PL 3244912 T3 PL3244912 T3 PL 3244912T3
- Authority
- PL
- Poland
- Prior art keywords
- lixisenatide
- treatment
- diabetes mellitus
- mellitus patients
- pediatric type
- Prior art date
Links
- XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 title 1
- 229960001093 lixisenatide Drugs 0.000 title 1
- 108010004367 lixisenatide Proteins 0.000 title 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15151488 | 2015-01-16 | ||
| PCT/EP2016/050804 WO2016113404A1 (en) | 2015-01-16 | 2016-01-15 | Treatment of pediatric type 2 diabetes mellitus patients with lixisenatide |
| EP16700758.2A EP3244912B1 (en) | 2015-01-16 | 2016-01-15 | Treatment of pediatric type 2 diabetes mellitus patients with lixisenatide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3244912T3 true PL3244912T3 (pl) | 2021-12-20 |
Family
ID=52354814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16700758T PL3244912T3 (pl) | 2015-01-16 | 2016-01-15 | Leczenie liksysenatydem pacjentów pediatrycznych z cukrzycą typu 2 |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US20160235818A1 (enExample) |
| EP (1) | EP3244912B1 (enExample) |
| JP (1) | JP7274258B2 (enExample) |
| KR (1) | KR102614574B1 (enExample) |
| CN (1) | CN107405386A (enExample) |
| AR (1) | AR103415A1 (enExample) |
| AU (1) | AU2016207964B2 (enExample) |
| CL (1) | CL2017001843A1 (enExample) |
| CR (1) | CR20170376A (enExample) |
| EA (1) | EA035423B1 (enExample) |
| ES (1) | ES2895513T3 (enExample) |
| IL (1) | IL253460B (enExample) |
| MX (1) | MX381944B (enExample) |
| PH (1) | PH12017501290A1 (enExample) |
| PL (1) | PL3244912T3 (enExample) |
| PT (1) | PT3244912T (enExample) |
| SG (1) | SG11201705755UA (enExample) |
| TN (1) | TN2017000292A1 (enExample) |
| TW (1) | TWI706779B (enExample) |
| WO (1) | WO2016113404A1 (enExample) |
| ZA (1) | ZA201704512B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3228320T (pt) | 2008-10-17 | 2020-03-26 | Sanofi Aventis Deutschland | Combinação de uma insulina e de um agonista do glp-1 |
| SG10201500871TA (en) | 2009-11-13 | 2015-04-29 | Sanofi Aventis Deutschland | Pharmaceutical composition comprising a glp-1 agonist and methionine |
| CN107206058A (zh) | 2014-12-12 | 2017-09-26 | 赛诺菲-安万特德国有限公司 | 甘精胰岛素/利西拉来固定比率配制剂 |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| DE102019129444A1 (de) * | 2019-10-31 | 2021-05-06 | Lts Lohmann Therapie-Systeme Ag | Lagtime-Verkürzung/Eisspray |
| US20240201166A1 (en) * | 2021-04-11 | 2024-06-20 | Vikas Khurana | Diagnosis and treatment of congestive colon failure (ccf) |
| WO2024133412A1 (en) | 2022-12-21 | 2024-06-27 | Novo Nordisk A/S | Methods and systems for estimating fbg value from cgm data |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| AR075204A1 (es) * | 2009-01-29 | 2011-03-16 | Boehringer Ingelheim Int | Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2 |
| US20120231022A1 (en) * | 2009-05-28 | 2012-09-13 | Amylin Pharmaceuticals, Inc. | Glp-1 receptor agonist compounds for sleep enhancement |
| SI2324853T1 (sl) * | 2009-11-13 | 2015-12-31 | Sanofi-Aventis Deutschland Gmbh | Liksisenatid kot dodatek metforminu pri zdravljenju sladkorne bolezni tipa 2 |
| EP2707017B1 (en) * | 2011-05-13 | 2015-09-16 | Sanofi-Aventis Deutschland GmbH | Lixisenatide and metformin for treatment of diabetes type 2 |
| US9821032B2 (en) * | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| WO2013003449A2 (en) * | 2011-06-27 | 2013-01-03 | Phasebio Pharmaceuticals, Inc. | Methods of treatment with glp-1 receptor agonists |
| JP6367115B2 (ja) * | 2011-08-29 | 2018-08-01 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | ２型糖尿病患者の血糖コントロールに使用する組合せ医薬 |
| SG11201401175SA (en) * | 2011-10-28 | 2014-09-26 | Sanofi Aventis Deutschland | Treatment protocol of diabetes type 2 |
-
2016
- 2016-01-14 AR ARP160100087A patent/AR103415A1/es unknown
- 2016-01-14 US US14/995,910 patent/US20160235818A1/en not_active Abandoned
- 2016-01-14 TW TW105101028A patent/TWI706779B/zh active
- 2016-01-15 PL PL16700758T patent/PL3244912T3/pl unknown
- 2016-01-15 EP EP16700758.2A patent/EP3244912B1/en active Active
- 2016-01-15 SG SG11201705755UA patent/SG11201705755UA/en unknown
- 2016-01-15 JP JP2017537500A patent/JP7274258B2/ja active Active
- 2016-01-15 MX MX2017009294A patent/MX381944B/es unknown
- 2016-01-15 ES ES16700758T patent/ES2895513T3/es active Active
- 2016-01-15 AU AU2016207964A patent/AU2016207964B2/en active Active
- 2016-01-15 TN TNP/2017/000292A patent/TN2017000292A1/en unknown
- 2016-01-15 PT PT16700758T patent/PT3244912T/pt unknown
- 2016-01-15 WO PCT/EP2016/050804 patent/WO2016113404A1/en not_active Ceased
- 2016-01-15 CR CR20170376A patent/CR20170376A/es unknown
- 2016-01-15 CN CN201680016033.2A patent/CN107405386A/zh active Pending
- 2016-01-15 KR KR1020177022646A patent/KR102614574B1/ko active Active
- 2016-01-15 EA EA201791611A patent/EA035423B1/ru not_active IP Right Cessation
-
2017
- 2017-07-04 ZA ZA2017/04512A patent/ZA201704512B/en unknown
- 2017-07-13 IL IL253460A patent/IL253460B/en unknown
- 2017-07-14 CL CL2017001843A patent/CL2017001843A1/es unknown
- 2017-07-14 PH PH12017501290A patent/PH12017501290A1/en unknown
-
2019
- 2019-02-04 US US16/266,873 patent/US20190365864A1/en not_active Abandoned
-
2020
- 2020-09-22 US US17/028,400 patent/US20210187075A1/en not_active Abandoned
-
2023
- 2023-08-07 US US18/366,130 patent/US20240173384A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL253460A0 (en) | Lixanitide treatment in pediatric patients with type 2 diabetes | |
| PL3268029T3 (pl) | Leczenie pacjentów z cukrzycą typu 2 | |
| SMT202100488T1 (it) | Trattamento dell'ipoglicemia post-bariatrica con exendina(9-39) | |
| PL3749308T3 (pl) | Leczenie pacjentów z klasyczną chorobą fabry’ego migalastatem | |
| GB201612165D0 (en) | Combinations for the treatment of type 2 diabetes | |
| IL254500A0 (en) | Treatment of patients with type 2 diabetes | |
| GB201707207D0 (en) | Treatment of type 1 diabetes | |
| GB201403996D0 (en) | Traditional chinese medicine composition for the treatment of diabetes | |
| SI3139948T1 (sl) | Zdravljenje diabetesa tipa 1 z uporabo GLP-1 in anti-IL-21 | |
| GB201915641D0 (en) | Glucose-responsive insulin analogs and methods of use thereof | |
| IL250666A0 (en) | A peptide for the treatment of diabetes mellitus type 2 and its complications | |
| IL270788A (en) | Sulfonylurea compounds in the treatment of disease associated with uv-induced damage | |
| HK1239556A1 (en) | Treatment of pediatric type 2 diabetes mellitus patients with lixisenatide | |
| PL3710043T3 (pl) | Fgf10 do leczenia chorób serca | |
| HK1244688A1 (en) | Treatment of type 2 diabetes mellitus patients | |
| PT3139948T (pt) | Tratamento de diabetes usando glp-1 e anti-il-21 | |
| GB201716026D0 (en) | Mental health patients | |
| GB201304462D0 (en) | Therapeutic vaccine for treatment of type 2 diabetes and impaired glucose tolerance |